By Judith E. Karp
This is a well timed compilation of recent techniques within the molecular pathogenesis and molecular remedy of acute myelogenous leukemia (AML). the point of interest is on chosen serious molecular determinants of AML pathogenesis and pathophysiology and the exploitation of those elements by way of diversified healing brokers and modalities. there's an emphasis all through at the bidirectional move of information among the medical and laboratory arenas.
Read Online or Download Acute Myelogenous Leukemia (Contemporary Hematology) PDF
Similar hematology books
''Boldly and elegantly, Wailoo analyzes not just the position of physicians yet of analysis hospitals and pharmaceutical businesses. moreover, he indicates how such things as race, gender, and way of life prompted how physicians outlined and replied to the very illnesses that have been known as into life by means of the hot applied sciences they hired.
Complement factor: Transfusion drugs and Hemotherapy 2004, Vol. 31, Suppl. 1
This crucial tools guide for immunohematologists (or hematologists and immunohematologists) offers details on genes that encode antigens on pink blood cells, platelets and neutrophils. The publication starts by means of masking normal innovations in molecular biology and particular protocols akin to DNA instruction, PCR-RFLP and allele-specific PCR.
The preeminent e-book on melanoma cytogenetics—now in a precious new version Like its profitable predecessors, melanoma Cytogenetics, 3rd variation keeps to supply authoritative insurance of neoplastic procedures on the chromosomal point of genomic association. Now up-to-date and increased, this new version comprises precise info at the newest advances within the box, incorporating an enormous volume of latest cytogenetic in addition to molecular genetic info from the newest easy and scientific investigations.
- The Blood Group Antigen FactsBook, Second Edition
- Human Blood Plasma Proteins: Structure and Function
- mTOR Inhibition for Cancer Therapy: Past, Present and Future
- Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia
Extra info for Acute Myelogenous Leukemia (Contemporary Hematology)
Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of hematological malignancies. Blood Rev 1992;6:63-73. 59. Shyam K, Cosby LA, Sartorelli AC. Synthesis and evaluation of N,N' -bis(arylsulfonyl)hydrazines as antineoplastic agents. J Med Chern 1985;28:525-527. 60. Shyam K, Furubayashi R, Hrubiec RT, Cosby LA, Sartorelli AC. 1,2-Bis(arylsulfonyl)hydrazines. 2. The influence of arylsulfonyl and aralkylsulfonyl substituents on antitumor and alkylating activity.
Molecular biology of the cell. In: Alberts B, Bray D, Lewis I, Raff M, Roberts K, Watson JD, eds. , 1994:721-785. Ravandi F, Talpaz M, Estrov Z. Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies. Clin Cancer Res 2003;9:535-550. Scheijen B, Griffin ID. Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene 2002;21 :3314-3333. Frank DA. STAT signaling in the pathogenesis and treatment of cancer. Mol Med 1999;5:432-456.
Chapter 1 I AML Treatment: Biological Perspective 17 41. Issa IP, Garcia-Manero G, Mannari R, et al. Minimal effective dose of the hypomethylating agent decitabine in hematopoietic malignancies. Blood 2001;98:594-595. 42. Issa IP, Garcia-Manero G, Giles Fl, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2' -deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004; I03(5): 1635-1640. 43. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.